Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma

Fig. 4

The relationship between the CXCR3 pathway and tumor immunogenicity A Comparison of TMB between the CXCR3-high and CXCR3-low groups in the ICI cohort. B Comparison of NAL between the CXCR3-high and CXCR3-low groups in the ICI cohort. C Comparison of DDR mutations between the CXCR3-high and CXCR3-low groups in the ICI cohort. D Comparison of TMB between the CXCR3-high and CXCR3-low groups in the TCGA cohort. E Comparison of NAL between the CXCR3-high and CXCR3-low groups in the TCGA cohort. F Comparison of DDR mutations between the CXCR3-high and CXCR3-low groups in the TCGA cohort. G Comparison of MANTIS scores between the CXCR3-high and CXCR3-low groups in the TCGA cohort. H The correlation between CXCR3 pathway activation and TMB in the ICI cohort. I The correlation between CXCR3 pathway activation and TNB in the ICI cohort

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us